SOURCE: Perma-Fix Environmental Services, Inc.

Perma-Fix Environmental Services, Inc. Logo

March 01, 2016 10:09 ET

Perma-Fix to Participate in Panel Discussion at the 2nd Annual Gabelli & Company Waste and Environmental Services Symposium on March 3, 2016

ATLANTA, GA--(Marketwired - March 01, 2016) - Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the "Company") has been invited to participate in a panel discussion at the 2nd Annual Gabelli & Company Waste & Environmental Services Symposium being held on March 3, 2016 at the Andaz 5th Avenue Hotel in New York City.

Dr. Louis F. Centofanti, Chief Executive Officer will participate in a panel discussion on Thursday, March 3rd at 11:30 a.m. Eastern time, followed by a Q&A fireside chat with senior industry management and institutional investors.

About Gabelli & Company

G.Research, LLC, an institutional research and brokerage firm, is a subsidiary of GAMCO Investors, Inc. (NYSE: GBL). Gabelli & Company is the marketing name for the registered broker dealer G.research, LLC. G.research, LLC, One Corporate Center Rye, NY 10580. Member of FINRA and SIPC. For more information, please visit

About Perma-Fix Environmental Services

Perma-Fix Environmental Services, Inc. is a nuclear services company and leading provider of nuclear and mixed waste management services. The Company's nuclear waste services include management and treatment of radioactive and mixed waste for hospitals, research labs and institutions, federal agencies, including the Department of Energy (DOE), the Department of Defense (DOD), and the commercial nuclear industry. The Company's nuclear services group provides project management, waste management, environmental restoration, decontamination and decommissioning, new build construction, and radiological protection, safety and industrial hygiene capability to our clients. The Company operates four nuclear waste treatment facilities and provides nuclear services at DOE, DOD, and commercial facilities, nationwide.

Through Perma-Fix Medical S.A., our majority-owned Polish subsidiary, we have also developed a new process to produce Tc-99m, a widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world.

Please visit us on the World Wide Web at

Contact Information

  • Contacts:
    David K. Waldman-US Investor Relations
    Crescendo Communications, LLC
    (212) 671-1021

    Herbert Strauss-European Investor Relations
    +43 316 296 31